Literature DB >> 27484508

Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity.

Kamilia M Amin1, Flora F Barsoum1, Fadi M Awadallah2, Nehal E Mohamed1.   

Abstract

Efforts to develop new antitumor agents are now directed towards multitarget therapies that are believed to have high potency and low tendency to resistance compared to conventional drugs. Herein, we highlighted the synthesis and antitumor activity of five series of phthalazine-based compounds featuring a variety of bioactive chemical fragments at position 1 of the phthalazine nucleus. The antitumor activity of the target compounds was performed against fourteen cancer cell lines where all compounds were active in the nanomolar level. In addition, the mechanism of action of the target compounds was investigated through an enzymatic inhibitory assay against VEGFR-2 and EGFR kinases, revealing potent and preferential activity toward VEGFR-2. Binding mode of the most active compounds was studied using docking experiment.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cytotoxicity; Docking; EGFR; Phthalazine; VEGFR-2

Mesh:

Substances:

Year:  2016        PMID: 27484508     DOI: 10.1016/j.ejmech.2016.07.049

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  5 in total

1.  Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.

Authors:  Caolin Wang; Shan Xu; Liang Peng; Bingliang Zhang; Hong Zhang; Yingying Hu; Pengwu Zheng; Wufu Zhu
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

2.  Metal-free domino amination-Knoevenagel condensation approach to access new coumarins as potent nanomolar inhibitors of VEGFR-2 and EGFR.

Authors:  Essam M Eliwa; Marcel Frese; Ahmed H Halawa; Maha M Soltan; Larissa V Ponomareva; Jon S Thorson; Khaled A Shaaban; Mohamed Shaaban; Ahmed M El-Agrody; Norbert Sewald
Journal:  Green Chem Lett Rev       Date:  2021-09-24       Impact factor: 6.016

3.  Synthesis of Novel Phthalazinedione-Based Derivatives with Promising Cytotoxic, Anti-bacterial, and Molecular Docking Studies as VEGFR2 Inhibitors.

Authors:  Samir M El Rayes; Gaber El Enany; Ibrahim A I Ali; Wessam Ibrahim; Mohamed S Nafie
Journal:  ACS Omega       Date:  2022-06-27

4.  Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer.

Authors:  Esraa A Abdelsalam; Amer Ali Abd El-Hafeez; Wagdy M Eldehna; Mahmoud A El Hassab; Hala Mohamed M Marzouk; Mahmoud M Elaasser; Nageh A Abou Taleb; Kamilia M Amin; Hatem A Abdel-Aziz; Pradipta Ghosh; Sherif F Hammad
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

5.  Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.

Authors:  Frangky Sangande; Elin Julianti; Daryono Hadi Tjahjono
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.